
Graphite Bio debuts corporate brand campaign with ‘Cure’ aspirations, even years ahead of drug approval
It’s tough to stand out in the gene editing field, so Graphite Bio adopted an uncommon biotech tactic — marketing.
The clinical-stage biotech — founded during the early days of the pandemic and going public just over a year ago — is still likely many years away from an approved drug. Its first, a sickle cell disease “gene correction” candidate, is currently in a Phase I/II study. Yet the biotech’s first corporate campaign rolled out this month confidently promotes its ambitions for a cure.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,300+ biopharma pros reading Endpoints daily — and it's free.